Prof. Dr. Rainer Riedl

Arbeit an der ZHAW

Tätigkeit

• Leiter Kompetenzzentrum für Wirkstoffforschung
• Leiter Fachgruppe Organische Chemie und Medizinalchemie

Netzwerk

Mitglied in Netzwerken

• Schweizerische Akademie der Technischen Wissenschaften
• Biotechnet Switzerland
• Studienstiftung des Deutschen Volkes
• Swiss Chemical Society
• Alexander von Humboldt Foundation

ORCID digital identifier

ORCID ID: 0000-0003-2534-1963

Social Media

linkedin

Projekte

• NEXTPro / Projektleiter:in / laufend
• Targeting the innate immune system for Multiple Sclerosis / Projektleiter:in / laufend
• Small molecules targeting CD93-signaling for the treatment of acute myeloid leukemia / Projektleiter:in / laufend
• Peptidic active ingredients III / Projektleiter:in / abgeschlossen
• Alzheimer's dementia / Projektleiter:in / abgeschlossen
• Evaluation of the potential of PROTACs / Projektleiter:in / abgeschlossen
• Peptidic active ingredients II / Projektleiter:in / abgeschlossen
• Antibiotika gegen hochresistente Gram-negative Bakterien / Projektleiter:in / abgeschlossen
• Innovative Immunotherapy Approach / Projektleiter:in / abgeschlossen
• Therapie für den NRAS-Melanom-Subtyp / Projektleiter:in / abgeschlossen
• Synthesis of peptidic active ingredients / Projektleiter:in / abgeschlossen
• Plattform zur Identifizierung von Wirkstofftargets / Projektleiter:in / abgeschlossen
• Protease-Inhibitoren gegen SARS-CoV-2 / Projektleiter:in / abgeschlossen
• Extrazelluläre Vesikel für den Transport von antimikrobiellen Proteinen zum Zielgewebe / Stellv. Projektleiter:in / abgeschlossen
• Developing novel and effective therapies for treatment of childhood brain cancers / Projektleiter:in / abgeschlossen
• Entwicklung neuer Therapieansätze zur Behandlung von Krebs / Projektleiter:in / abgeschlossen
• Entwicklung einer neuartigen Behandlung gegen pathologische Haut- und Sehnenkalzifizierung auf Basis eines Gasotransmitters / Projektleiter:in / abgeschlossen
• Plants and Minerals in Byzantine Popular Pharmacy. A New Multidisciplinary Approach / Stellv. Projektleiter:in / abgeschlossen
• Entwicklung von niedermolekularen Verbindungen zur Blockierung des CD93 Signalwegs bei Leukämiepatienten / Projektleiter:in / abgeschlossen
• Inflammasominhibitoren - Entwicklung neuer Hemmstoffe / Projektleiter:in / abgeschlossen
• Modulatoren der MMP-Hemopexin-Domäne / Projektleiter:in / abgeschlossen
• Neue Antibiotika: RNA-Polymerase-Inhibitoren / Projektleiter:in / abgeschlossen
• Behandlung von Brandwunden / Projektleiter:in / abgeschlossen
• Antivirale Wirkstoffe / Projektleiter:in / abgeschlossen
• MMP-Inhibitor-Hydrogel zur Wundheilung / Projektleiter:in / abgeschlossen
• Induktion der Wirkstoffbildung bei Actinomyceten / Stellv. Projektleiter:in / abgeschlossen
• Ein topisches Antiinfektiva / Projektleiter:in / abgeschlossen
• Morbillivirus cell entry machinery: mechanisms, structures and antiviral drug discovery / Co-Projektleiter:in / abgeschlossen
• Identifizierung und Charakterisierung von Wirkstoffen aus Actinomyceten aus der Schweiz gegen pathogene Bakterien / Projektleiter:in / abgeschlossen
• Virus cell entry machinery: antiviral drug discovery / Projektleiter:in / abgeschlossen
• Novel Antimicrobials for Life-Threatening Infections / Projektleiter:in / abgeschlossen
• Dynamic combinatorial chemistry in drug discovery / Projektleiter:in / abgeschlossen
• New antileishmanial and antitrypanosomal drugs / Projektleiter:in / abgeschlossen
• New drugs for the treatment of protozoal infections derived from natural products / Projektleiter:in / abgeschlossen
• Kinetische Struktur-Aktivitäts-Beziehungen und röntgenkristallographische Bestimmung des Bindungsmodus von niedermolekularen Wirkstoffmolekülen / Projektleiter:in / abgeschlossen
• Development of high temperature resistant, synergistic biocidal products for protection of PVC against microbial infestation for commercial product applications / Projektleiter:in / abgeschlossen
• HIT to LEAD to Preclinical Candidate development of a Transcription Repressor Inhibitory Compound (TRIC) that increases antibiotic susceptibility of multidrug resistant staphylococci / Projektleiter:in / abgeschlossen
• Forschungs- und Entwicklungsarbeiten auf dem Gebiet von potentiellen Wirkstoffen gegen Diabetes / Projektleiter:in / abgeschlossen
• Prevention of undesired interactions between biocides and additives in synthetic materials to improve efficacy and to reduce the necessary amount of biocides / Projektleiter:in / abgeschlossen
• Development of a software to analyse chemical and biological data: CyBy2 / Projektleiter:in / abgeschlossen
• HIT to LEAD to Candidate development of a Transcription Repressor Inhibitory Compound (TRIC), which switches off bacterial resistance to a broad band antibiotic / Projektleiter:in / abgeschlossen
• Isolation, Identifikation und medizinalchemische Optimierung von biogenen Wirkstoffen / Projektleiter:in / abgeschlossen
• Identification of novel targets and drug candidates against multi-drug resistant bacteria / Projektleiter:in / abgeschlossen

Publikationen

Beiträge in wissenschaftlicher Zeitschrift, peer-reviewed

• Scherer, M. et al. (2026) 'Protection against lethal canine distemper virus infection by a dual epitope-targeting synthetic antibody', Nature Communications, 17(1), p. 103. doi: 10.1038/s41467-025-67600-z.
• Nasi, S. et al. (2025) 'Allosteric activators of cystathionine γ lyase to augment endogenous hydrogen sulfide and inhibit pathologic calcification', Pharmacological Research, 219(107869). doi: 10.1016/j.phrs.2025.107869.
• Rimle, L. et al. (2025) 'Dissecting structural requirements of leucinostatin A derivatives for antiprotozoal activity and mammalian toxicity', Journal of Medicinal Chemistry, 68(4), pp. 4237–4258. doi: 10.1021/acs.jmedchem.4c01989.
• Fischer, T. et al. (2024) 'Phthalimide derivatives as a new class of papain-like protease inhibitors in SARS-CoV-2', Archiv der Pharmazie, 358(1), p. e2400714. doi: 10.1002/ardp.202400714.
• Fischer, T. et al. (2024) 'Phthalimide derivatives as a new class of papain‐like protease inhibitors in SARS‐CoV‐2', Archiv der Pharmazie, 358(1), p. e2400714. doi: 10.1002/ardp.202400714.
• Pliatsika, D., Blatter, C. and Riedl, R. (2024) 'Targeted protein degradation : current molecular targets, localization, and strategies', Drug Discovery Today, 29(11), p. 104178. doi: 10.1016/j.drudis.2024.104178.
• Kalbermatter, D. et al. (2023) 'Structure and supramolecular organization of the canine distemper virus attachment glycoprotein', Proceedings of the National Academy of Sciences of the United States of America, 120(6), p. e2208866120. doi: 10.1073/pnas.2208866120.
• Sabani, B. et al. (2023) 'A novel surface functionalization platform to prime extracellular vesicles for targeted therapy and diagnostic imaging', Nanomedicine: Nanotechnology, Biology and Medicine, 47(102607). doi: 10.1016/j.nano.2022.102607.
• Bagatella, S. et al. (2022) 'Bovine neutrophil chemotaxis to Listeria monocytogenes in neurolisteriosis depends on microglia-released rather than bacterial factors', Journal of Neuroinflammation, 19(304). doi: 10.1186/s12974-022-02653-1.
• Kiss, C. et al. (2022) 'Structure of a hydrophobic leucinostatin derivative determined by host lattice display', Acta Crystallographica. Section D: Structural Biology, 78(12), pp. 1439–1450. doi: 10.1107/S2059798322010762.
• Brand, M. et al. (2022) 'Discovery of a dual SENP1 and SENP2 inhibitor', International Journal of Molecular Sciences, 23(20), p. 12085. doi: 10.3390/ijms232012085.
• Fischer, T. and Riedl, R. (2022) 'Paracelsus" legacy in the faunal realm : drugs deriving from animal toxins', Drug Discovery Today, 27(2), pp. 567–575. doi: 10.1016/j.drudis.2021.10.003.
• Brand, M. et al. (2021) 'Antiprotozoische Struktur‐Aktivitäts‐Beziehungen von synthetischen Leucinostatin‐Derivaten und Aufklärung ihres Wirkprinzips', Angewandte Chemie, 133(28), pp. 15741–15749. doi: 10.1002/ange.202102153.
• Shrestha, N. et al. (2021) 'Highly potent host-specific small-molecule inhibitor of paramyxovirus and pneumovirus replication with high resistance barrier', mBio, 12(6), p. e0262121. doi: 10.1128/mBio.02621-21.
• Neidhart, B. et al. (2021) 'Tissue inhibitor of metalloproteinase (TIMP) peptidomimetic as an adjunctive therapy for infectious keratitis', Biomacromolecules, 22(2), pp. 629–639. doi: 10.1021/acs.biomac.0c01473.
• Brand, M. et al. (2021) 'Antiprotozoal structure–activity relationships of synthetic leucinostatin derivatives and elucidation of their mode of action', Angewandte Chemie: International Edition, 60(28), pp. 15613–15621. doi: 10.1002/anie.202102153.
• Zizzari, A. T. et al. (2021) 'New perspectives in oral peptide delivery', Drug Discovery Today, 26(4), pp. 1097–1105. doi: 10.1016/j.drudis.2021.01.020.
• Shrestha, N. et al. (2021) 'Antiviral screen against canine distemper virus-induced membrane fusion activity', Viruses, 13(1), p. 128. doi: 10.3390/v13010128.
• Arn, F. et al. (2020) 'Isolation and identification of actinomycetes strains from Switzerland and their biotechnological potential', Chimia, 74(5), pp. 382–390. doi: 10.2533/chimia.2020.382.
• Fischer, T. and Riedl, R. (2020) 'Challenges with matrix metalloproteinase inhibition and future drug discovery avenues', Expert Opinion on Drug Discovery, 16(1), pp. 75–88. doi: 10.1080/17460441.2020.1819235.
• Kalbermatter, D. et al. (2020) 'Cryo-EM structure of the prefusion state of canine distemper virus fusion protein ectodomain', Journal of Structural Biology: X, 4, p. 100021. doi: 10.1016/j.yjsbx.2020.100021.
• Lindenmann, U. et al. (2020) 'Discovery of a class of potent and selective non‐competitive sentrin‐specific protease 1 inhibitors', ChemMedChem, 15(8), pp. 675–679. doi: 10.1002/cmdc.202000067.
• Fischer, T. and Riedl, R. (2019) 'Inhibitory antibodies designed for matrix metalloproteinase modulation', Molecules, 24(12), p. 2265. doi: 10.3390/molecules24122265.
• Fischer, T. et al. (2019) 'High consistency of structure-based design and x-ray crystallography : design, synthesis, kinetic evaluation and crystallographic binding mode determination of biphenyl-N-acyl-β-D-glucopyranosylamines as glycogen phosphorylase inhibitors', Molecules, 24(7), p. 1322. doi: 10.3390/molecules24071322.
• Höck, S. and Riedl, R. (2019) 'CyBy2 : a strongly typed, purely functional framework for chemical data management', Journal of Cheminformatics, 11(80). doi: 10.1186/s13321-019-0403-2.
• Fischer, T., Gazzola, S. and Riedl, R. (2019) 'Approaching target selectivity by de novo drug design', Expert Opinion on Drug Discovery, 14(8), pp. 791–803. doi: 10.1080/17460441.2019.1615435.
• Fischer, T., Senn, N. and Riedl, R. (2019) 'Design and structural evolution of matrix metalloproteinase inhibitors', Chemistry – A European Journal, 25(34), pp. 7960–7980. doi: 10.1002/chem.201805361.
• Gall, F. et al. (2019) 'Von der Natur inspiriertes Wirkstoffdesign : kristallographische Detektion eines selbstgenerierten Inhibitor‐Grundgerüsts', Angewandte Chemie, 131(12), pp. 4091–4096. doi: 10.1002/ange.201812348.
• Gall, F. et al. (2019) 'Drug design inspired by nature : crystallographic detection of an auto‐tailored protease inhibitor template', Angewandte Chemie: International Edition, 58(12), pp. 4051–4055. doi: 10.1002/anie.201812348.
• Kalbermatter, D. et al. (2018) 'Primary resistance mechanism of the canine distemper virus fusion protein against a small-molecule membrane fusion inhibitor', Virus Research, 259, pp. 28–37. doi: 10.1016/j.virusres.2018.10.003.
• Agnello, S. et al. (2018) 'Eine strukturelle Evaluierung medizinalchemischer Strategien gegen Wirkstoffresistenzen', Angewandte Chemie, 131(11), pp. 3336–3383. doi: 10.1002/ange.201802416.
• Agnello, S. et al. (2018) 'A Structural view on medicinal chemistry strategies against drug resistance', Angewandte Chemie, 58(11), pp. 3300–3345. doi: 10.1002/anie.201802416.
• Abu Eid, S. et al. (2017) 'Emodin : a compound with putative antidiabetic potential, deteriorates glucose tolerance in rodents', European Journal of Pharmacology, 798, pp. 77–84. doi: 10.1016/j.ejphar.2017.01.022.
• Fischer, T. and Riedl, R. (2017) 'Development of a non-hydroxamate dual matrix metalloproteinase (MMP)-7/-13 inhibitor', Molecules, 22(9). doi: 10.3390/molecules22091548.
• Fischer, T. and Riedl, R. (2017) 'Cover profile : targeted fluoro positioning for the discovery of a potent and highly selective matrix metalloproteinase inhibitor', ChemistryOpen, 6(2), p. 167. doi: 10.1002/open.201700042.
• Chellat, M. F. and Riedl, R. (2017) 'Pseudouridimycin : the first nucleoside analogue that selectively inhibits bacterial RNA polymerase', Angewandte Chemie: International Edition, 56(43), pp. 13184–13186. doi: 10.1002/anie.201708133.
• Fischer, T. and Riedl, R. (2017) 'Targeted fluoro positioning for the discovery of a potent and highly selective matrix metalloproteinase inhibitor', ChemistryOpen, 6(2), pp. 192–195. doi: 10.1002/open.201600158.
• Fischer, T. and Riedl, R. (2017) 'Cover picture : targeted fluoro positioning for the discovery of a potent and highly selective matrix metalloproteinase inhibitor (ChemistryOpen 2/2017)', ChemistryOpen, 6(2), p. 165. doi: 10.1002/open.201700043.
• Chellat, M. F. and Riedl, R. (2017) 'Pseudouridimycin : das erste Nukleosid-Analogon, das bakterielle RNA-Polymerase selektiv inhibiert', Angewandte Chemie, 129(43), pp. 13364–13366. doi: 10.1002/ange.201708133.
• Senn, N. et al. (2017) 'Targeted polypharmacology : discovery of a highly potent non-hydroxamate dual matrix metalloproteinase (MMP)-10/-13 inhibitor', Journal of Medicinal Chemistry, 60(23), pp. 9585–9598. doi: 10.1021/acs.jmedchem.7b01001.
• Chellat, M. F., Raguž, L. and Riedl, R. (2016) 'Antibiotikaresistenzen gezielt überwinden', Angewandte Chemie, 128(23), pp. 6710–6738. doi: 10.1002/ange.201506818.
• Chellat, M. F., Raguž, L. and Riedl, R. (2016) 'Targeting antibiotic resistance', Angewandte Chemie: International Edition, 55(23), pp. 6600–6626. doi: 10.1002/anie.201506818.
• Fischer, T. and Riedl, R. (2016) 'Molecular recognition of the catalytic zinc(II) ion in MMP-13 : structure-based evolution of an allosteric inhibitor to dual binding mode inhibitors with improved lipophilic ligand efficiencies', International Journal of Molecular Sciences, 17(3/314). doi: 10.3390/ijms17030314.
• Lanz, J. and Riedl, R. (2015) 'Merging allosteric and active site binding motifs : de novo generation of target selectivity and potency via natural-product-derived fragments', ChemMedChem, 10(3), pp. 451–454. doi: 10.1002/cmdc.201402478.
• Todorova, M. et al. (2015) 'Highly oxygenated sesquiterpenes in Artemisia alba Turra', Phytochemistry, 110, pp. 140–149. doi: 10.1016/j.phytochem.2014.12.008.
• Fischer, T. and Riedl, R. (2013) 'Strategic targeting of multiple water-mediated interactions : a concise and rational structure-based design approach to potent and selective MMP-13 inhibitors', ChemMedChem, 8(9), pp. 1457–1461. doi: 10.1002/cmdc.201300278.
• Höck, S. and Riedl, R. (2012) 'chemf : a purely functional chemistry toolkit', Journal of Cheminformatics, 4(38). doi: 10.1186/1758-2946-4-38.
• Höck, S. and Riedl, R. (2012) 'CyBy2 : a structure-based data management tool for chemical and biological data', Chimia, 66(3), pp. 132–134. doi: 10.2533/chimia.2012.132a.
• Höck, S. et al. (2010) 'Thermal cleavage of the Fmoc protection group', Chimia, 64(3), pp. 200–202. doi: 10.2533/chimia.2010.200.
• Heuser, S. et al. (2006) 'Synthesis of novel cyclopropylic sulfones and sulfonamides acting as glucokinase activators', Tetrahedron Letters, 47(16), pp. 2675–2678. doi: 10.1016/j.tetlet.2006.02.110.
• Supekova, L. et al. (2002) 'Genomic effects of polyamide/DNA interactions on mRNA expression', Chemistry & Biology, 9(7), pp. 821–827. doi: 10.1016/S1074-5521(02)00174-6.
• Berkessel, A. and Riedl, R. (2000) 'Combinatorial de novo synthesis of catalysts : how much of a hit-structure is needed for activity?', Journal of Combinatorial Chemistry, 2(3), pp. 215–219. doi: 10.1021/cc990073i.
• Riedl, R., Tappe, R. and Berkessel, A. (1998) 'Probing the scope of the asymmetric dihydroxylation of polymer-bound olefins : monitoring by HRMAS NMR allows for reaction control and on-bead measurement of enantiomeric excess', Journal of the American Chemical Society, 120(35), pp. 8994–9000. doi: 10.1021/ja980183d.
• Berkessel, A. and Riedl, R. (1997) 'Fluorescence reporters for phosphodiesterase activity', Angewandte Chemie: International Edition, 36(13-14), pp. 1481–1483. doi: 10.1002/anie.199714811.
• Berkessel, A. and Riedl, R. (1997) 'Fluoreszenz-Reporter für Phosphodiesterase-Aktivität', Angewandte Chemie, 109(13-14), pp. 1518–1520. doi: 10.1002/ange.19971091313.

Bücher, peer-reviewed

Riedl, R. (1998) Kombinatorische de novo Synthese von künstlichen Phosphorsäurediesterasen : Inaugural-Dissertation zur Erlangung des Doktorgrades der Mathematisch-Naturwissenschaftlichen Fakultät der Universität zu Köln. Doctoral dissertation. Universität zu Köln. Available at: http://kups.ub.uni-koeln.de/573/.

Weitere Publikationen

• Hess, S. et al. (2025) A NanoBRET-based assay monitoring interactions in the USP18 signaling hub identifies the first cell-penetrant small molecule compromising USP18/ISG15 binding. bioRxiv. doi: 10.1101/2025.03.30.646166.
• Riedl, R. (2023) 'Development of small-molecule drugs for the treatment of leukemia', Transfer, 2023(1), p. 7. doi: 10.21256/zhaw-30047.
• Brand, M. et al. (2021) Back Cover: Antiprotozoal structure–activity relationships of synthetic leucinostatin derivatives and elucidation of their mode of action (Angew. Chem. Int. Ed. 28/2021). Wiley. doi: 10.1002/anie.202104896.
• Brand, M. et al. (2021) Rücktitelbild: Antiprotozoische Struktur-Aktivitäts-Beziehungen von synthetischen Leucinostatin-Derivaten und Aufklärung ihres Wirkprinzips (Angew. Chem. 28/2021). Wiley. doi: 10.1002/ange.202104896.
• Gall, F. et al. (2019) 'Durch die Natur inspiriertes Wirkstoffdesign', Transfer, 2019(1), p. 6. doi: 10.21256/zhaw-30046.
• Gall, F. et al. (2019) 'Cover picture : drug design inspired by nature : crystallographic detection of an auto‐tailored protease inhibitor template (Angew. Chem. Int. Ed. 12/2019)', Angewandte Chemie: International Edition, 58(12), p. 3653. doi: 10.1002/anie.201901671.
• Gall, F. M. et al. (2019) Titelbild: Von der Natur inspiriertes Wirkstoffdesign : kristallographische Detektion eines selbstgenerierten Inhibitor‐Grundgerüsts (Angew. Chem. 12/2019). Wiley. doi: 10.1002/ange.201901671.
• Lanz, J. and Riedl, R. (2015) Cover Picture: Merging allosteric and active site binding motifs : de novo generation of target selectivity and potency via natural‐product‐derived fragments (ChemMedChem 3/2015). Wiley. doi: 10.1002/cmdc.201590003.
• Riedl, R. (2014) 'Fighting the resistance', Horizon 2020 Projects, 2014(4), p. 130.
• Riedl, R. (2014) 'Nicht nur Metalloproteasen im Visier', Chemie Plus, 2014(4), pp. 30–31.
• Riedl, R. (2013) 'Bridging the disciplines : cancer diagnostics & treatment', Pan European Networks: Science & Technology, 7, pp. 240–241.
• Riedl, R. and Höck, S. (2013) 'CyBy² : clevere Handhabung strukturbasierter Datensätze', Transfer, 2013(1), p. 3. doi: 10.21256/zhaw-2864.
• Fischer, T. and Riedl, R. (2013) Back Cover: Strategic targeting of multiple water‐mediated interactions : a concise and rational structure‐based design approach to potent and selective MMP‐13 inhibitors (ChemMedChem 9/2013). Wiley. doi: 10.1002/cmdc.201390039.
• Riedl, R. (2013) 'Drug discovery through a chemist's eyes', International Innovation - EuroFocus, 18, p. 103.
• Riedl, R. (2013) 'Organic chemistry : the heart and soul of drug discovery', International Innovation - EuroFocus, 18, pp. 104–105.
• Riedl, R. and Fischer, T. (2012) 'Structure based design and synthesis of novel MMP inhibitors', in 19th EuroQSAR: «Knowledge Enabled Ligand Design», Vienna, Austria, 26-30 August 2012.
• Fischer, T. and Riedl, R. (2012) 'Design, synthesis and biological testing of novel MMP-inhibitors', in Fall Meeting 2012 of the Swiss Chemical Society, Zurich, 13 September 2012.
• Riedl, R. and Brand, M. (2012) 'Synthese und medizinalchemische Optimierung von Tetrazyklinanaloga', À Jour: SVC - Chemie, Life Sciences & Biotechnologie, 2012(1), pp. 10–11.
• Riedl, R. and Höck, S. (2012) 'Enhancing CyBy2 : visualization of structure activity relationships of large datasets', in Fall Meeting 2012 of the Swiss Chemical Society, Zurich, 13 September 2012.
• Riedl, R. and Höck, S. (2011) 'CyBy2 : a modular rich client for the chemical and biological information management', in Fall Meeting 2011 of the Swiss Chemical Society, Lausanne, 9 September 2011.
• Riedl, R. et al. (2011) 'Structure based design and synthesis of novel MMP inhibitors', in Fall Meeting 2011 of the Swiss Chemical Society, Lausanne, 9 September 2011.
• Riedl, R., Brand, M. and Sephton, M. (2011) 'Synthesis of tetracycline analogues', in Fall Meeting 2011 of the Swiss Chemical Society, Lausanne, 9 September 2011.
• Riedl, R., Höck, S. and Kunz, L. (2010) 'Profiling H-bond properties of fragments', in Fall Meeting 2012 of the Swiss Chemical Society, Zurich, 16 September 2010.
• Riedl, R. and Fischer, T. (2010) 'Fragment based scaffold hopping in drug discovery', in Fall Meeting 2012 of the Swiss Chemical Society, Zurich, 16 September 2010.

Mündliche Konferenzbeiträge und Abstracts

• Ehirchiou, D. et al. (2025) 'Development of allosteric activators of cystathionine γ lyase (CSE) to augment hydrogen sulfide (H2S) and inhibit pathologic cartilage calcification', in Annals of the Rheumatic Diseases. Elsevier, pp. 112–113. doi: 10.1016/j.ard.2025.05.149.
• Ehirchiou, D. et al. (2025) 'Positive allosteric modulators (PAMS) of cystathionine gamma lyase (CSE) increase hydrogen sulfide (H2S) and inhibit NLRP3 activation', in Annals of the Rheumatic Diseases. Elsevier, pp. 116–117. doi: 10.1016/j.ard.2025.05.154.
• Ehirchiou, D. et al. (2025) 'Development of allosteric activators of cystathionine γ lyase (CSE) to augment hydrogen sulfide (H2S) and inhibit pathologic cartilage calcification', in Osteoarthritis and Cartilage. Elsevier, p. S452. doi: 10.1016/j.joca.2025.02.660.
• Riedl, R. (2024) 'Competencies in drug discovery', in tfz Innovation Inside Pharma, Rotkreuz, Switzerland, 23 October 2024.
• Rimle, L. et al. (2024) 'Molecular basis for leucinostatin A toxicity in mammals', in Biochimica et Biophysica Acta (BBA) - Bioenergetics. Elsevier. doi: 10.1016/j.bbabio.2024.149316.
• Riedl, R. (2024) 'Center of excellence for drug discovery', in Competencies in Drug Discovery, Wädenswil, Switzerland, 6 June 2024.
• Bagatella, S. et al. (2022) 'Microglia, rather than bacterial factors, mediate bovine neutrophil chemotaxis in neurolisteriosis', in Journal of Comparative Pathology. Elsevier, p. 61. doi: 10.1016/j.jcpa.2023.03.073.
• Abu Eid, S. et al. (2016) 'Emodin, a compound with acclaimed antidiabetic potential, deteriorates glucose tolerance in obese mice', in Diabetologia. Springer, p. S343. doi: 10.1007/s00125-016-4046-9.
• Abu Eud, S. et al. (2015) 'Emodin, eine mutmaßlich anti-diabetisch wirksame Verbindung, beeinträchtigt die Glukosetoleranz adipöser Mäuse', in Wiener Klinische Wochenschrift. Springer, p. 735. doi: 10.1007/s00508-015-0838-z.
• Riedl, R. (2013) 'Tackling antibiotic resistance', in ILMAC 2013, 19. Internationale Fachmesse für Laboratoriums- und Verfahrenstechnik, Messtechnik und Automatik in der Chemie (ILMAC), Basel, 24.-27. September 2013.
• Riedl, R. (2011) 'Drug discovery in the academic setting', in 3. Wädenswiler Chemietag «Medizinalchemie - Fokus Wirkstoffentwicklung», Wädenswil, 16. Juni 2011.
• Riedl, R. (2010) 'Structure based drug design', in Biotech in Medicine - Olten Meeting, Olten, 24. November 2010.
• Riedl, R. (2010) 'Structure activity relationship within a gene switching system', in Symposium - Synthetic Biotechnology, Basel, 18.-19. November 2010.

Patente und Patentanmeldungen

• Adams, Michael; Kemmler, Michael; Tobler, Andreas; Pliatsika, Dimanthi; Riedl, Rainer,

  2025.

  Compounds for treatment of cancer.

  Patentnummer WO2025172389 A1

  (2025-08-21)

  .

  Verfügbar unter: https://worldwide.espacenet.com/patent/search?q=pn%3DWO2025172389A1

• Riedl, Rainer; Brand, Michael; Bommeli, Elias; Ochsenbein, Adrian; Riether, Carsten,

  2024.

  CD93 inhibitors.

  Patentnummer WO2024115637 A1

  (2024-06-06)

  .

  Verfügbar unter: https://worldwide.espacenet.com/patent/search?q=pn%3DWO2024115637A1

• Adams, Michael; Kemmler, Michael; Pliatsika, Dimanthi; Riedl, Rainer,

  2024.

  Topical treatment of skin cancer using oligopeptides.

  Patentnummer WO2024033418 A1

  (2024-02-15)

  .

  Verfügbar unter: https://worldwide.espacenet.com/patent/search?q=pn%3DWO2024033418A1

• Knechtle, Philipp; Gombert, Frank Otto; Riedl, Rainer; Lindenmann, Urs; Krebs, Walter; Wipfli, Dennis; Albert, Ina; Wegmann, Sandro; Schmid, Andrina,

  2023.

  Novel antifungal compounds.

  Patentnummer WO2023001905 A1

  (2023-01-26)

  .

  Verfügbar unter: https://worldwide.espacenet.com/patent/search?q=pn%3DWO2023001905A1

• So, Alexander; Busso, Natalie; Nasi, Sonia; Brand, Michael; Gall, Flavio Max; Riedl, Rainer; Germann, Stefan,

  2022.

  Methods and compositions for treating conditions associated with hypermineralization.

  Patentnummer WO2022194953 A1

  (2022-09-22)

  .

  Verfügbar unter: https://worldwide.espacenet.com/patent/search?q=pn%3DWO2022194953A1

• So, Alexander; Busso, Natalie; Nasi, Sonia; Brand, Michael; Gall, Flavio; Riedl, Rainer,

  2022.

  Methods and compositions for treating conditions associated with hypermineralization.

  Patentnummer EP4059498 A1

  (2022-09-21)

  .

  Verfügbar unter: https://worldwide.espacenet.com/patent/search?q=pn%3DEP4059498A1

• Adams, Michael; Kemmler, Michael; Riedl, Rainer; Pliatsika, Dimanthi; Imanidis, Georgios; Herzig, Susanne; Kaiser, Marcel; Mäser, Pascal,

  2022.

  Treatment of skin disorders.

  Patentnummer WO2022167656 A1

  (2022-08-11)

  .

  Verfügbar unter: https://worldwide.espacenet.com/patent/search?q=pn%3DWO2022167656A1

• Agnello, Stefano; Adams, Michael; Kaiser, Marcel; Mäser, Pascal; Urban, Alexander; Raguz, Luka; Riedl, Rainer,

  2018.

  Antiprotozoal compounds.

  Patentnummer EP3345917 A1

  (2018-07-11)

  .

  Verfügbar unter: https://worldwide.espacenet.com/patent/search?q=pn%3DEP3345917A1

• Schneider, Peter; Riedl, Rainer; Tigges, Marcel; Gitzinger, Marc; Pieren, Michel; Levi, Assaf; Sephton, Mark; Schellhorn, Birgit; Züger, Patrik; Brand, Michael; Gygax, Daniel; Spies, Peter,

  2015.

  Composition for treatment of pathogens that are resistant to tetracyclines.

  Patentnummer EP2950793 A1

  (2015-12-09)

  .

  Verfügbar unter: https://worldwide.espacenet.com/patent/search?q=pn%3DEP2950793A1

• Weichert, Andreas Gerhard; Barrett, David Gene; Heuser, Stefan; Riedl, Rainer; Tebbe, Mark Joseph; Zaliani, Andrea,

  2011.

  Substituted arylcyclopropylacetamides as glucokinase activators.

  Patentnummer EP1585739 B1

  (2011-04-20)

  .

  Verfügbar unter: https://worldwide.espacenet.com/patent/search?q=pn%3DEP1585739B1

• Weichert, Andreas; Barrett, David; Heuser, Stefan; Riedl, Rainer; Tebbe, Mark; Zaliani, Andrea,

  2004.

  Heteroaryl compounds.

  Patentnummer WO2004063194 A1

  (2004-07-29)

  .

  Verfügbar unter: https://worldwide.espacenet.com/patent/search?q=pn%3DWO2004063194A1

Interessenbindungen

Aktuelle Interessenbindungen

ULTIMATE MEDICINE AG: Beratung
Beratungstätigkeit im Bereich der pharmazeutischen Wirkstoffforschung und Wirkstoffentwicklung für die Firma Ultimate Medicine AG, gegründet und registriert in der Schweiz unter der Firmennummer CHE-438.939.011., Zürich
08 / 2024 - heute

Vergangene Interessenbindungen

Czech Academy of Sciences: Beratung
Mitglied der Evaluierungskommission der Tschechischen Akademie der Wissenschaften für die Evaluierung des Instituts für Organische Chemie und Biochemie, Prag, Prag
04 / 2025 - 12 / 2025

Zurück